发布时间
2026/03/25 04:5812 分钟前源站更新
2026/03/25 04:5812 分钟前首次抓取
2026/03/25 04:5812 分钟前发布时间
12 分钟前源站更新
12 分钟前首次抓取
12 分钟前用于追踪这条内容的来源与记录标识。
Source
原始链接
发布时间
2026/03/25 04:5812 分钟前源站更新
2026/03/25 04:5812 分钟前首次抓取
2026/03/25 04:5812 分钟前发布时间
12 分钟前源站更新
12 分钟前首次抓取
12 分钟前用于追踪这条内容的来源与记录标识。
Source
原始链接
Big Pharma Is Hooked on Chinese Licensing Deals For US drugmakers, the expanding tie-ups with Chinese companies mean lower costs and more access to breakthrough treatments. For critics in Washington, the deals spell risk.
发布时间
50 天前
2026-08-19 04:01:04 UTC
源站更新
50 天前
2026-08-19 04:01:04 UTC
首次抓取
50 天前
2026-08-19 04:12:14 UTC
美国大药企大量与中国生物技术公司达成授权协议，以降低成本并获取创新疗法，但国会提出法案加强审查，担忧国家安全和产业流失。今年已达 32 笔交易，默克等巨头依赖中国研发的药物。
U.S. drugmakers are signing record numbers of licensing deals with Chinese biotech firms to cut costs and access innovation, but lawmakers warn of risks to national security and domestic industry. At least 32 deals were struck this year, with Merck and others relying on
用于追踪这条内容的来源与记录标识。
